New hope for HS sufferers: LAD191 enters Mid-Stage trial
NCT ID NCT07151937
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new injectable drug called LAD191 in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants will receive either LAD191, a placebo, or an active comparator (adalimumab) to see if LAD191 reduces skin lesions by at least 50% over 16 weeks. The goal is to find a more effective treatment for HS.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LAD191 (injected under the skin)
What this could lead to
If successful, LAD191 could offer a new treatment option to reduce painful abscesses and nodules in people with hidradenitis suppurativa.
What could go wrong
This is an early Phase 2 study with only 200 participants. The drug may not work better than placebo, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIDRADENITIS SUPPURATIVA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital de Manises
RECRUITINGManises, 46940, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••